About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 71162 record(s)
Req # A-2023-001242
All documents and correspondence which the rapid test supplier BTNX, Inc., submitted to Health Canada as it applied for approval to sell the COVID-19 antigen test with the device identifiers COV-19CHC, COV-19CHC1, COV-19CHC2, COV-19CHC5, COV-19CHC25.Organization: Health Canada
August 2024
Req # A-2023-001300
Correspondence relating to any abbreviated new drug submission (ANDS) filed since January 1, 2023 where the medicinal ingredient is estradiol alone and the product’s indications include the treatment of postmenopausal moderate to severe dyspareunia.Organization: Health Canada
August 2024
Req # A-2023-001318
Data regarding the issuance of an No Objection Letter (NOL) on 2021-10-16 Notifiable Change (NC) # 257449 regarding changes to the drug manufacturing process of Comirnaty.Organization: Health Canada
August 2024
Req # A-2023-001324
The Product Information Template: Regulatory Enrollment Process (the equivalent of Section #67 of the previous Health Canada (HC)/Sante Canda (SC)-3011 Drug Submission Application Form) for the Mesalazine Abbreviated New Drug Submission (ANDS),…Organization: Health Canada
August 2024
Req # A-2023-001326
Rrecords containing information regarding the mock-ups of every label to be used in connection with the Mesalazine Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024
Req # A-2023-001327
The most recent Certified Product Information Document (CPID) submitted for the Mesalazine Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024
Req # A-2023-001328
The most recent Module 2.3: Quality Overall Summary (QOS) submitted by the sponsor for the Mesalazine Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024
Req # A-2023-001367
All correspondence between Health Canada employee Pierre Sabourin or David Boudreau and BTNX, Inc., and other correspondence these two Health Canada employees sent or received concerning BTNX, between April 1, 2020 and November 30, 2022.Organization: Health Canada
August 2024
Req # A-2023-001438
Records regarding all funding allocated by Health Canada for LGBTQ+-specific mental health and/or suicide prevention initiatives in the past three fiscal years. Details of any research, studies, or surveys conducted by or on behalf of Health Canada…Organization: Health Canada
August 2024
Req # A-2023-001443
The cover letter which accompanied the Abbreviated New Drug Submission (ANDS) for Aripiprazole for which an ANDS was added to the Health Canada List of Generic Submissions Under Review (GSUR) on January 19, 2024. Screening Acceptance letter for the…Organization: Health Canada
August 2024